ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Neurology

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,389Medicare Part D Prescriptions Filled, Including Refills

Rank: 3 out of 379

$1.68M Total Retail Price of All Prescriptions

Rank: 12 out of 379

884 Patients Receiving at Least One Drug in Part D
68%Patients 65 Years and Older
46% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Pennsylvania
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

2% of this provider’s 884 patients filled at least one prescription for a schedule three drug, compared to an average of 2%.

Risky Drugs to Seniors

4% of this provider’s 4,914 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

29% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$201 was the average price of a prescription from this provider, compared to $278 among peers.

Prescriptions per Patient

9 is the average number of prescriptions (including refills) per patient, compared to an average of 9.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Pennsylvania
NAMENDA 565 542 1 6
GABAPENTIN 483 261 2 2
CARBIDOPA-LEVODOPA 449 428 3 1
LEVETIRACETAM 424 198 4 3
CITALOPRAM HBR 269 138 5 28
DONEPEZIL HCL 238 215 6 4
LAMOTRIGINE 226 33 7 7
DIVALPROEX SODIUM ER 224 33 8 21
BACLOFEN 203 74 9 10
TOPIRAMATE 198 34 10 5
TIZANIDINE HCL 191 60 11 25
EXELON 187 184 12 20
AMITRIPTYLINE HCL 165 95 R 13 22
PRAMIPEXOLE DIHYDROCHLORIDE 155 109 14 11
PROPRANOLOL HCL 151 106 15 32
TRAMADOL HCL 150 67 16 34
SERTRALINE HCL 150 97 16 30
ROPINIROLE HCL 132 100 18 9
ESCITALOPRAM OXALATE 131 112 19 56
CYMBALTA 114 68 20 31
AGGRENOX 106 100 21 57
PRIMIDONE 105 85 22 8
VIMPAT 95 0 23 26
VENLAFAXINE HCL ER 86 56 24 52
PHENYTOIN SODIUM EXTENDED 84 69 25 23
METHOCARBAMOL 78 36 R 26 88
ARICEPT 73 73 27 166
SUMATRIPTAN SUCCINATE 68 16 28 50
CLOPIDOGREL 68 57 28 54
CARISOPRODOL 64 31 R 30 40
ZONISAMIDE 63 29 31 24
COPAXONE 63 0 31 13
TRAZODONE HCL 62 39 33 36
LYRICA 62 52 33 14
CARBAMAZEPINE XR 61 36 35 79
PAROXETINE HCL 61 47 35 55
PLAVIX 54 51 37 66
TEGRETOL XR 54 19 37 51
DILANTIN 53 0 39 17
DEPAKOTE 51 0 40 92
BUSPIRONE HCL 51 46 40 65
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.